Aspect Biosystems

Aspect Biosystems develops bioprinted tissue therapeutics: implantable allogeneic tissues built on its platform, which combines proprietary bioprinting technology, computational design tools, therapeutic cells and biomaterials. The tissues are intended to replace, repair or supplement biological functions for metabolic and endocrine diseases.

The company partners with pharmaceutical and biotechnology companies, including Novo Nordisk, to bring cell therapies toward the clinic. Its work spans process development, manufacturing, quality assurance and clinical operations.

Aspect Biosystems is a Canadian biotechnology company; its co-founder Sam Wadsworth joined in co-founding the company in 2013. The website states a team of over 100 people and more than US$350M in capital raised. Open roles are listed in Vancouver, BC and Fremont, California.

Product: Bioprinted, implantable allogeneic tissue therapeutics built on a bioprinting and biomanufacturing platform.